VitalStone Financial’s ARK Genomic Revolution ETF ARKG Stock Holding History

VitalStone Financial’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.86K	Sell	346 -1	-0.3%	-$25	0.01%	273
2024 Q2	$8.15K	Sell	347 -235	-40%	-$5.93K	0.01%	275
2024 Q1	$17K	Sell	582 -90	-13%	-$2.71K	0.01%	238
2023 Q4	$22K	Sell	672 -5	-0.7%	-$136	0.02%	213
2023 Q3	$16K	Sell	677 -723	-52%	-$23.6K	0.01%	207
2023 Q2	$43K	Buy	1,400 +32	+2%	+$1.01K	0.02%	373
2023 Q1	$81K	Buy	1,368 +39	+3%	+$1.21K	0.07%	90
2022 Q4	$37K	Buy	+1,329	New	+$42.2K	0.03%	197

Other funds holding ARKG

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

VitalStone Financial's ARKG Position: Q3 2024 in Review

VitalStone Financial reduced its ARK Genomic Revolution ETF (ARKG) stake by 0.29% in Q3 2024, selling an estimated $25 and leaving 346 shares worth $8.86K. The position accounts for 0.01% of the portfolio, ranked #273.

VitalStone Financial first reported a position in ARKG in Q4 2022 and has held it in 8 quarters since. The position peaked at $81K in Q1 2023. 239 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

VitalStone Financial held 346 shares of ARK Genomic Revolution ETF worth $8.86K as of Q3 2024.
VitalStone Financial sold 1 ARK Genomic Revolution ETF share in Q3 2024, an estimated $25.
ARK Genomic Revolution ETF made up 0.01% of VitalStone Financial's portfolio in Q3 2024, its #273 holding.
VitalStone Financial first reported a position in ARK Genomic Revolution ETF in Q4 2022 and has held it in 8 quarters since.
VitalStone Financial's ARK Genomic Revolution ETF position peaked at $81K in Q1 2023.
239 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on VitalStone Financial's 13F filing for Q3 2024, filed 11 Oct 2024.